NS1209 and Lidocaine in Patients With Peripheral Neuropathic Pain

NS1209 and Lidocaine in Patients With Peripheral Neuropathic Pain: a Randomized, Double-Blind, Placebo-Controlled, Crossover Study

Purpose: To evaluate the efficacy, tolerability and safety of NS1209 compared to lidocaine and placebo in patients with peripheral chronic neuropathic pain.

Inclusion Criteria:

• Age >18 years
• Neuropathic pain and allodynia after a peripheral nerve injury (VAS >= 4)

Exclusion Criteria:

• Patients who cannot cooperate and do no understand Danish
• Fertile women
• Clinically significant abnormality or disease
• Drug and alcohol abuse
• Clinically abnormal ECG
• Hypersensitivity to any of the treatments
• Patients in treatment with cimetedin, antidepressants, antipsychotics, antiepileptics except gabapentin, anticoagulants, Na channel blockers and beta blockers
• Patients who have previously been treated in a NS1209 study
• Patients treated with an investigational drug